


# Discovery points to new approach to treating liver cancer

December 4 2023, by Mary Martialay



Reduced DDX5 protein levels in human HCCs associated with increased tumor grade and poor patient survival following sorafenib treatment. **A** Immunohistochemistry (IHC) with DDX5 antibody of tissue microarrays (TMA) comprised of human normal liver samples and HCCs of grades I-III. Representative images at 20× magnification. IHC images of TMAs (24 normal samples and 30 HCCs) are shown in Supplementary Figs. S1A and S2–S3. **B** Quantification of DDX5-positive cells from TMAs of normal liver and HCCs (>1000 cells were quantified per tumor). \*\**p*

Citation: Discovery points to new approach to treating liver cancer (2023, December 4) retrieved 28 April 2024 from

<https://medicalxpress.com/news/2023-12-discovery-approach-liver-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.